US 12,220,394 B2
Pharmaceutical composition for prevention or treatment of kidney damage
Takashi Wada, Ishikawa (JP); Kengo Furuichi, Ishikawa (JP); Norihiko Sakai, Ishikawa (JP); Yasunori Iwata, Ishikawa (JP); Akinori Hara, Ishikawa (JP); Yusuke Nakade, Ishikawa (JP); Kenji Hamase, Fukuoka (JP); and Masashi Mita, Tokyo (JP)
Assigned to National University Corporation Kanazawa University, Kanazawa (JP); and Kagami Inc., Ibaraki (JP)
Appl. No. 16/972,898
Filed by National University Corporation Kanazawa University, Kanazawa (JP); and Kagami Inc., Ibaraki (JP)
PCT Filed Jun. 6, 2019, PCT No. PCT/JP2019/022607
§ 371(c)(1), (2) Date Dec. 7, 2020,
PCT Pub. No. WO2019/235559, PCT Pub. Date Dec. 12, 2019.
Claims priority of application No. 2018-109731 (JP), filed on Jun. 7, 2018.
Prior Publication US 2021/0220309 A1, Jul. 22, 2021
Int. Cl. A61K 31/198 (2006.01); A61K 9/00 (2006.01); A61P 13/12 (2006.01)
CPC A61K 31/198 (2013.01) [A61K 9/0053 (2013.01); A61P 13/12 (2018.01)] 6 Claims
 
1. A method for treatment of kidney disease, comprising: administrating D-alanine to a subject in need thereof, wherein the kidney disease is chronic kidney disease, ischemia-induced kidney disorder, or inflammation-induced kidney disorder.